High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation: A Case Report-Reference-Cited by-同舟云学术

High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation: A Case Report

Published:2023 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Uchida Yasuhiro¹,Koyama Daisuke¹,Manabe Kazuya¹,Suzuki Kengo¹,Asano Naomi¹,Endo Mamiko¹,Fukatsu Masahiko¹,Sano Takahiro¹,Hayashi Kiyohito¹,Takano Motoki¹,Takahashi Hiroshi¹,Kimura Satoshi¹,Ikezoe Takayuki¹

Affiliation:

1. Department of Hematology, Fukushima Medical University, Fukushima, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_2179-23/_pdf

Reference14 articles.

1. 1. Koyama D, Kikuchi J, Kuroda Y, Ohta M, Furukawa Y. AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells. Cancer Sci 2020.

2. 2. Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 376: 917-927, 2017.

3. 3. Jabbour EJ, Sasaki K, Haddad FG, et al. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol 98: 658-665, 2023.

4. 4. Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543: 733-737, 2017.

5. 5. Mauro MJ, Hughes TP, Kim DW, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia 2023.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Myeloid Leukemia in Renal Transplantation Patients in the Era of Tyrosine Kinase Inhibitors: A Case Report and Review of the Literature;Nephron;2024